Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus.

Acemannan, a complex carbohydrate shown to stimulate interleukin-1, tumor necrosis factor alpha and prostaglandin E2 production by macrophages, has also demonstrated antiviral activity in vitro against human immunodeficiency virus, Newcastle disease virus and influenza virus. A pilot study was undertaken to determine acemannan's effect in 49 feline immunodeficiency virus (FIV) infected cats with clinical signs of disease (Stage 3, 4 or 5), 23 of which had severe lymphopenia. Cats received acemannan either by intravenous (Group 1) or subcutaneous (Group 2) injection once weekly for 12 weeks, or by daily oral (Group 3) administration for 12 weeks. Upon entry into the study, cats were randomly assigned to one of the three groups. Laboratory analyses were performed at the beginning of the study and at Weeks 6 and 12. Cats were allowed to continue with a predetermined maintenance regimen of acemannan after completing the 12-week study. Thirteen cats died during the course of treatment. Upon necropsy, the most frequent histopathologic findings were neoplastic, kidney and pancreatic disease. Friedman's two-way ANOVA test showed no significant differences in efficacy among groups administered acemannan by the different routes. Therefore, groups were combined and a signed-ranks test was used to determine changes over time. A significant increase was seen in lymphocyte counts (P < 0.001). Neutrophil counts decreased significantly (P = 0.007), as did incidence of sepsis (P = 0.008). When cats entering with lymphopenia were analyzed separately, a much greater increase in lymphocyte counts was noted (235%) compared with non-lymphopenic cats (42%). A survival rate of 75% was found for all three groups. Thirty-six of 49 animals are alive 5-19 months post-entry. These results suggest that acemannan therapy may be of significant benefit in FIV-infected cats exhibiting clinical signs of disease.     

Presumptive subcutaneous surgical transplantation of a urinary bladder transitional cell carcinoma in a dog

A urinary bladder mass in a 12-year-old spayed female West Highland White Terrier was diagnosed after exploratory surgery and biopsy as a transitional cell carcinoma. Four months later the dog presented with an ulcerated plaque-like cutaneous lesion at the previous surgical incision site; concurrent inguinal lymphadenopathy and recurrence of the urinary bladder mass were identified. Transitional cell carcinoma was diagnosed at all 3 sites. Although a definitive relationship cannot be established between the initial surgery for urinary bladder mass and the resultant subcutaneous lesion, surgical implantation should be considered as a source for the neoplastic cells.     

Experimental acute yellow-wood (Terminalia oblongata) intoxication in sheep

SUMMARY An aqueous suspension of air-dried, hammer-milled leaf of Terminalla oblongata (yellow-wood) was administered to sheep by gavage, as a single dose of 5 to 20 g (dry weight)/kg body weight. Doses of 15 g/kg, or more, caused depression, Inappetence, abdominal pain and reduced ruminal movements within 24 to 48 h and some sheep also showed dyspnoea, oplsthotonus and champing of the Jaws. Haematology and blood gas and acid-base measurements were unaffected. In sheep given a dose of 12.5 g/kg, or more, plasma osmolality, aspartate aminotransferase activity and potassium and bilirubin concentrations Increased while plasma total protein markedly decreased and plasma sodium concentration and alkaline phosphatase activity remained normal. Most sheep were necropsled 48 h after dosing. The liver showed zonal hepatocellular necrosis, the pattern of which varied with the dose given. No renal lesions were observed, although one sheep given a very high dose became azotaemic and hyperkalaemic. Hydrothorax, hydroperlcardlum and ascltes developed In sheep given doses of 15 or 20 g/kg.     

Transmutation and functional representation of heterogeneous landscapes

Models of local small-scale ecological processes can be used to describe related processes at larger spatial scales if the influences of increased scale and heterogeneity are carefully considered. In this paper we consider the changes in the functional representation of an ecological process that can occur as one moves from a local small-scale model to a model of the aggregate expression of that process for a larger spatial extent. We call these changes spatial transmutation. We specifically examine landscape heterogeneity as a cause of transmutation. Spatial transmutation as a consequence of landscape heterogeneity is a source of error in the prediction of aggregate landscape behavior from smaller scale models. However, we also demonstrate a procedure for taking advantage of spatial transmutation to develop appropriately scaled landscape functions. First a mathematical function describing the process of interest as a local function of local variables is defined. The spatial heterogeneity of the local variables is described by their statistical distribution in the landscape. The aggregate landscape expression of the local process is then predicted by calculating the expected value of the local function, explicitly integrating landscape heterogeneity. Monte Carlo simulation is used to repeat the local-to-landscape extrapolation for a variety of landscape patterns. Finally, the extrapolated landscape results are regressed on landscape variables to define response functions that explain a useful fraction of the total variation in landscape behavior. The response functions are hypotheses about the functional representation of the local process at the larger spatial scale.     

A diet formulated from by‐products and indigenous foodstuffs for laying hens

1. The performance of six commercial stocks of laying hens fed on a diet composed of home‐produced foodstuffs, not usually used for human consumption, was compared with that of birds fed on a conventional diet.

2. The experimental diet was calculated to be low in energy and methionine and high in fibre by conventional standards. Birds ate up to 12% more of this diet, but the calculated intakes of energy and methionine were less than those of the corresponding controls.

3. White stocks fed on the experimental diet produced seven eggs less per bird than controls while the production of brown stocks was essentially unaffected.

4. The gross efficiency of energy utilisation for egg production was better with the experimental diet.     

Rotaviral antibodies in cow's milk.

In the past, it has been reported that neonatal diets made from unheated cow's milk were superior to those made from heated cow's milk. It was observed that piglets were equally protected from rotaviral diarrhea when they were fed diets made from either unheated milk that came from a cow immunized against porcine rotavirus or from a cow that was not immunized. Because of this observation, we examined four pools of "normal" cows' colostrum and 58 samples of "normal" cow's milk for the presence of antibody to rotavirus. All pools of colostrum, collected in four different years, had immunofluorescent antibody titers of 1:100 to rotavirus. Seventy-two percent of the samples of milk were also positive--titer no higher than 1:10. Antibodies to rotavirus were found in cow's milk at a creamery prior to but not after pasteurization. Rotaviral antibodies were detected in one out of eight brands of milk bought at the market--perhaps indicating inadequate pasteurization for this brand. These results support the proposition that, at least in part, unheated milk is superior to heated milk because unheated milk contains antibody to an ubiquitous enteropathogen like rotavirus.     

Effect of benazepril and pimobendan on serum angiotensin‐converting enzyme activity in dogs

To support their combined use, the objective of the study was to evaluate the effects of benazepril and pimobendan on serum angiotensin‐converting enzyme (ACE) activity in dogs. A total of 48 healthy beagle dogs were randomized into four groups (n = 12 per group) in a parallel‐group design study: A (control, placebo twice daily (BID)); B (0.5–1.0 mg/kg benazepril once daily (SID) in the morning, placebo in the evening); C (0.25–0.5 mg/kg benazepril BID); D (0.25–0.5 mg/kg benazepril and 0.125–0.25 mg/kg pimobendan, both BID). The test items were administered orally for 15 days. Serum ACE activity was measured on days 1 and 15. Groups B, C and D had significantly lower average serum ACE activity compared to baseline and to the control group, on both days 1 and 15. There were no significant differences in average ACE activity between groups B, C and D. Noninferiority of group C to B was demonstrated. In conclusion, 0.25–0.5 mg/kg benazepril administered BID produced noninferior inhibition of serum ACE activity compared to 0.5–1.0 mg/kg benazepril dosed SID. Pimobendan had no significant effect on benazepril's action on serum ACE activity. The results support the use of benazepril BID in dogs and in combination with pimobendan.